A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)

Trial Profile

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Friedreich's ataxia
  • Focus Therapeutic Use
  • Acronyms MOXIe
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2017 According to a Reata Pharmaceuticals media release, the Company has initiated screening patients for Part 2 of MOXIe and plans to randomize the first patient during the second half of 2017.
    • 14 Aug 2017 According to a Reata Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) confirmed that the mFARS is an acceptable primary endpoint for Part 2 of the MOXIe trial for omaveloxolone in Friedreich's ataxia.
    • 26 Jun 2017 Planned number of patients changed from 108 to 172.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top